ABSTRACT
Introduction@#There is an urgent need to study client satisfaction in assessing the quality and availability of health care. Compliance with the needs of consumers of any care, its accessibility, professional ethics, speed of work, determining customer satisfaction allows for evidence-based decision-making. Therefore, satisfaction surveys should be conducted at short intervals and the results used for decision making. One hundred and fifty million people on the planet pay for their health care every year and face financial hardship. Hundreds of millions of them are living in poverty, according to the World Health Organization’s 2010 year report. Governments must ensure that all people receive health care and are protected from health-related financial risks. We believe that the current state of quality and access to health care in our country does not fully meet the needs of the population. 62.4% of customer satisfaction surveys conducted in 2013 that health care was inadequate. However, customer satisfaction surveys on health insurance coverage are rare. The process of providing discounted medicines through health insurance varies depending on the health needs of consumers and their budgetary capacity. Therefore, it is necessary to take into account the factors that affect customer satisfaction.@*Methods@#In our study, we looked by retrospective at health and health insurance reporting indicators, Satisfaction of customers who bought medicines at pharmacies with health insurance prescriptions was surveyed in a one-moment survey.</br> We collected information on the satisfaction status of 525 people who used health insurance prescriptions from 36 pharmacies from December 2018 to April 2019 and from January to February 2021 using preprocessed cards.@*Conclusion@#</br>1. The cost of diagnosis from the health insurance fund and the selection of drugs to be included in the list of drug price discounts are related to the prevalence of the disease in Mongolia. </br>2. Difficulties in accessing drug price reductions from the health insurance fund can lead to dissatisfaction with the approved budget and the availability of drugs on the list. </br>3. In the case of Ulaanbaatar pharmacies, the satisfaction rate of consumers who use the discounted price of medicines according to the health insurance prescription is 3.634 or 72.688% in the first stage survey and 3.912 ± 0.50 or 78.248% in the second stage survey.
ABSTRACT
Resumen Objetivo: Identificar estrategias orientadas a favorecer el acceso a medicamentos de interés en salud pública, de alto costo o protegidos por patentes, posiblemente aplicables al contexto colombiano. Metodología: revisión estructurada en PubMed/Medline, utilizando los términos MeSH: "health services accessibility", "pharmaceutical preparations", "policy", con filtros para artículos publicados en inglés y español, entre 2012 y 2017. Se incluyeron aquellos con información sobre estrategias o políticas que favorecieran el acceso a medicamentos de interés en salud pública de alto costo o protegidos por patentes. Las estrategias identificadas fueron agrupadas acorde con las cinco dimensiones del acceso a la atención en salud y medicamentos definidas por la Organización Mundial de la Salud: disponibilidad, asequibilidad, accesibilidad, aceptabilidad y calidad. Resultados: Se identificaron 62 artículos, de los cuales se incluyeron 18 y se consideraron 5 referencias adicionales. Se reconocieron 30 estrategias, distribuidas y clasificadas según las dimensiones del acceso: disponibilidad y asequibilidad, 15; accesibilidad, 6; aceptabilidad, 6; calidad, 2; estrategia transversal, 1. Conclusiones: Se identificaron estrategias claves para favorecer el acceso a medicamentos de interés en salud pública de alto costo o protegidos por patentes, dentro de las que se encuentran las negociaciones centralizadas de precios; el apoyo financiero público para la investigación, desarrollo y producción nacional de medicamentos genéricos; la aplicación de las flexibilidades del acuerdo sobre los "Aspectos de los derechos de propiedad intelectual relacionados con el comercio" y la implementación de programas de asistencia.
Abstract Objective: To identify strategies aimed to improve access to medicines of interest in public health with high cost or protected with patents, possibly applicable to the Colombian contextTo identify strategies aimed at promoting access to high-cost or patent-protected medicines of interest in public health, possibly applicable to the Colombian context.. Methodology: structured review in PubMed/Medline, using the MeSH terms: "health services accessibility", "pharmaceutical preparations", "policy", with filters for articles published in English and Spanish, between 2012 and 2017. Studies with information on strategies or policies that favored access to high-cost or patent-protected drugs of interest in public health were included. The strategies identified were grouped according to the five dimensions of access to health care and medicines defined by the World Health Organization: availability, affordability, accessibility, acceptability and quality. Results: 62 articles were identified, of which 18 were included, and 5 additional references were considered. 30 strategies were recognised, distributed and classified according to the dimensions of access: availability and affordability, 15; accessibility, 6; acceptability, 6; quality, 2; cross-cutting strategy, 1. Conclusions: Key strategies were identified to favor access to high-cost or patent-protected medicines of interest in public health, including centralized price negotiations; public financial support for national research, development and production of generic medicines; the application of the flexibilities of the agreement on "Aspects of intellectual property rights related to trade" and the implementation of care programs.
Resumo Objetivo: Identificar estratégias destinadas a favorecer o acesso a medicamentos de interesse em saúde pública, de alto custo ou protegidos por patentes, possivelmente aplicáveis ao contexto colombiano. Metodologia: Revisão estruturada no PubMed/Medline, usando os termos MeSH: "health services accessibility", "pharmaceutical preparations", "policy", com filtros para artigos publicados em inglês e espanhol, entre 2012 e 2017. Foram incluídos aqueles com informações sobre estratégias ou políticas que favoreciam o acesso a medicamentos de interesse em saúde pública de alto custo ou protegidos por patentes. As estratégias identificadas foram agrupadas de acordo com as cinco dimensões de acesso aos cuidados de saúde e medicamentos definidas pela Organização Mundial da Saúde: disponibilidade, alcançabilidade, acessibilidade, aceitabilidade e qualidade. Resultados: Foram identificados 62 artigos, dos quais 18 foram incluídos e 5 referências adicionais foram consideradas. 30 estratégias foram identificadas, distribuídas e classificadas de acordo com as dimensões do acesso: disponibilidade e alcançabilidade, 15; acessibilidade, 6; aceitabilidade, 6; qualidade 2; estratégia transversal, 1. Conclusões: Foram identificadas estratégias-chave para favorecer o acesso a medicamentos de interesse em saúde pública de alto custo ou protegidos por patentes, dentro das quais estão as negociações centralizadas de preços; o apoio financeiro público à pesquisa, desenvolvimento e produção nacional de medicamentos genéricos; a aplicação das flexibilidades do acordo sobre "Aspectos dos direitos de propriedade intelectual relacionados ao comércio" e a implementação de programas de assistência.
ABSTRACT
OBJECTIVE: To reflect the changes of medicine price level in China after canceling the maximum retail price limit, and to provide reference for the improvement of medicine price policy. METHODS: This research utilizes data of Chinese medicine economic information database of Chinese Pharmaceutical Association from January 2015 to March 2019 and compiles comprehensive and classified chained fisher price indexes among diverse policy control levels and different treatment categories. RESULTS: Over the past four years, the sale of west medicine(WM) by Chinese medical institutions showed a trend of decreasing price, with a decline of 13.99%. And the price of traditional Chinese medicine (TCM) showed a trend of first rising and then falling, with a decline of 3.54%. From the analysis on different policy control levels, the price of medical insurance WM, non-medical insurance WM, medical insurance TCM and non-medical insurance TCM decreased by 13.32%, 14.27%, 1.36% and 14.29%, respectively. The price of medical insurance TCM fell less. And the price of non-medical insurance TCM rose and fell too quickly in a short period of time, and its fluctuation was obvious. Among medical insurance medicines, the price of category A WM raised by 4.5%, while the prices of category B WM, category A TCM and category B TCM dropped by 15.90%, 0.66% and 1.47%, respectively. The price of essential WM, non-essential WM, essential TCM and non-essential TCM reduced by 13.72%, 13.90%, 3.70% and 3.60%, respectively. From the analysis on different treatment categories, the prices of diabetes medicines, hypertension medicines and systemic anti-infection medicines decreased by 6.78%, 10.42% and 12.72%, respectively. Anticancer medicines had largest price decline with 26.69%. CONCLUSION: After canceling the maximum retail price limit, the price of WM declines steadily, while the price of TCM first rises and then falls. The changes of medicine prices vary greatly at different policy control levels. The trends of medicine price reduction among different treatment categories are the same, but the differences are large.
ABSTRACT
Objective To research the difference of medicines prices in the new round of centralized purchasing from 10 provinces,and provide references for further perfecting centralized medicines procurement of provinces in China.Methods Based on the 2015 national sample hospital medicines procurement ranking list and the new round centralized procurement of every province,15 kinds of medicines are selected.By comparative studying,the difference of 15 medicines price among 10 provinces is analyzed.And the difference of prices between the domestic medicines and imported medicines in reference to WHO/HAl drug price standard survey method,the prices of medicines in each province and the international reference prices are analyzed.Results The medicine prices are different in different provinces.The medicines prices of Fujian Province are obviously lower than other provinces.The prices of a few imported medicines are obviously higher than those of domestic ones.Median prices ratios of some medicines exceed the reasonable range.Conclusion It is suggested that every province should refer to the useful experience of Fujian Province in medicines centralized procurement,to improve their centralized procurement plans.Every province should grant equal bids for imported patents,domestic generic drugs and original medicines,to make them have consistency bidding.The international reference price is incorporated into the price limit reference system,to make more reasonable price limit standard.
ABSTRACT
New healthcare reform has been achieved remarkable effects and had a lot of acceptance by people at home and abroad. As the reason of the historical and medical system problem, high Medicine Price still exists in the most area of China. It is necessary to establish a reasonable mechanism of drugpricing and improve financial efficiencies of medical reform to guarantee the smooth and healthy development of healthcare reform.
ABSTRACT
Through the system of medicine centralized bidding and purchasing, it intends to solve the problems of high medicine price and drug rebate; however, it failed which was against the willing. It requires exploding regardless hospital regulation system and the current drug production and circulation system to finally stop the high medicine price and drug debate.
ABSTRACT
Objective: To explore the imported medicine price’s pass-through effect on domestic western medicine’s price. Methods: Based on the time-series data from January 2003 to March 2013, the empirical research studied the effect of imported medicine’s price and other variables on domestic western medicine price. Results: The imported medicine’ price has short significant effect on domestic medicine. Conclusion: To reduce the effect of imported medicine price’s fluctuation, the government should intervene the medicine price moderately; the drug company and the hospital should pay attention to the efficacy and the promotion of the domestic western medicine.
ABSTRACT
Objective: To reasonably adjust the medical prices on the basis of cancelling drug prices policies. Methods: Taking the data from sample hospitals in Guangdong as example, to discuss how to establish model of medical service item pricing scientifically and reasonably. Results:The model of medical service item pricing has been established and practical care has been estimated. Conclusion:It needs to adjust the charging of medical technical services to achieve the prospective effects of medical reform.
ABSTRACT
OBJECTIVE:To tackle the problem of virtual-high drug price through reforming pricing mechanism of drugs. METHODS: To review the history of the pricing mechanism of medicines, analyzed the problems existed in the pricing mechanism and the reasons accountable for the high drug prices as well as the responsibilities of the related departments in the high drug prices, then a new pricing mechanism of medicines was put forward. RESULTS & CONCLUSIONS: The new pricing mechanism of drugs can bring down the drug prices to a large extent meanwhile increasing revenue for hospital even without the increase in financial appropriation. Hospitals can make profits in a way rather than from big examination of the patients, which can help reduce the medical costs paid by the common people.